Biopharma CEOs Less Confident In Deal-Making Environment
Across the biopharmaceutical industry, chief executives are less confident in the current deal landscape and turning their focus inward on executing on their scientific targets.
Kineticos, in partnership with Ipsos Healthcare and Demy-Colton, has released its quarterly Biopharma CEO Confidence Index, which it bills as a forward-looking indicator designed to measure C-suite sentiment and confidence in the biopharma industry's economy.
“One of the biggest thing[s] we're seeing is a shift in focus of biopharma CEOs in the last 3 quarters.
Kineticos, in partnership with Ipsos Healthcare and Demy-Colton, has released its quarterly Biopharma CEO Confidence Index, which it bills as a forward-looking indicator designed to measure C-suite sentiment and confidence in the biopharma industry's economy.
“One of the biggest thing[s] we're seeing is a shift in focus of biopharma CEOs in the last 3 quarters.